Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Aileron Therapeutics Inc (ALRN)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Aileron Therapeutics's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
4.2500 -1.1000    -20.56%
17/04 - Closed. Currency in USD ( Disclaimer )
After Hours
4.7000
+0.4500
+10.5882%
19:57:29 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 64,936
  • Bid/Ask: 4.3000 / 4.7400
  • Day's Range: 4.1200 - 5.2700
Aileron Therapeutics 4.2500 -1.1000 -20.56%

Aileron Therapeutics Inc Company Profile

 
Get an in-depth profile of Aileron Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

6

Equity Type

ORD

Aileron Therapeutics, Inc. is a clinical-stage chemoprotection oncology company. It is focused on developing medicines to make chemotherapy safer. Its ALRN-6924 product is a MDM2/MDMX dual inhibitor that leverages its peptide drug technology, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focused on treating patients with p53-mutated cancers. It is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects without interrupting chemotherapy’s destruction of cancer cells. It stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. ALRN-6924 can pause cell division in cells with wild type, p53, include normal bone marrow cells and ALRN-6924 has no activity against cancer cells with mutations in p53.

Contact Information

Address 285 Summer Street Suite 101
Boston, 02210
United States
Phone 617 995 0900
Fax 617 995 2410
Web www.aileronrx.com

Top Executives

Name Age Since Title
Reinhard J. Ambros 69 2013 Independent Lead Director
William Carl Fairey 59 2023 Independent Director
Josef H. von Rickenbach 69 2019 Independent Chairman
Alan A. Musso 62 2023 Independent Director
Manuel C. Aivado 54 2014 Director
Alan F. List 69 2018 Member of Scientific Advisory Board
Carol L. Prives - 2018 Member of Scientific Advisory Board
Ulrich Steidl - - Member of Scientific Advisory Board
Brian J. Druker 69 2018 Member of Scientific Advisory Board
James Brian Windsor 57 2023 CEO & Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

ALRN Comments

Write your thoughts about Aileron Therapeutics Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Stephen Kaczmarek
Stephen Kaczmarek May 10, 2022 2:37PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
this company has 9 employees and neg earnings. never had. a profitable quarter. I bought some shares instead of making a bet in Vegas. should have played the ponies instead. alrn = dead money
Reply
0 0
Report
Konstantinos Theodorides
Konstantinos Theodorides Feb 22, 2021 7:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ALRN-6924 is one of the most advanced late cancer treatments that can possibly save millions of lives. Do some research and you'll understand why this stock is critically undervalued atm.
Reply
4 0
Report
Stephen Kaczmarek
Stephen Kaczmarek Feb 22, 2021 7:33AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
it is a clinical stage company in Boston MA Big loser with some potential Neg earnings with no immediate prospects to gain market share I call it a Vegas stock Don't invest more than you can comfortably lose
Reply
0 0
Report
Roy mu
Roy mu Feb 16, 2021 4:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
cheap right now. Just bought 2000 shares. Would be a even more terrific entry price at 1.8, although unlikely to see such a low price.
Reply
1 0
Report
Roy mu
Roy mu Feb 16, 2021 4:02PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
no signal says buy at 1.8 just yet, still need to wait.
Reply
0 0
Report
Raul AlKhuwaitem
Raul AlKhuwaitem Feb 10, 2021 10:54PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Mid February results released.. It will be huge jump for ALRN.. I think this is the last opportunity to buy cheap within these two days.. Good luck guys.. I hope you got more than that..
Reply
3 0
Report
Konstantinos Theodorides
Konstantinos Theodorides Feb 10, 2021 10:54PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
couldn't say it better, strong buy and hold for this company. Will probably add more shares today. It will skyrocket once results are positive as the matters of research are truly significant. Its leade candidate targets tumor proteins for the treatment of a range of cancers. Aileron is also currently collaborating with Pfizer.
Reply
0 0
Report
Konstantinos Theodorides
Konstantinos Theodorides Feb 10, 2021 2:42PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
one of the last chances to add a dip imo🚀🚀
Reply
2 0
Report
Roy mu
Roy mu Feb 10, 2021 2:42PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Quickly loading up more
Reply
0 0
Report
Raul AlKhuwaitem
Raul AlKhuwaitem Feb 06, 2021 4:18AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
TNXP.. ATHX.. ALRN.. Working on Cancer reserch and they are very close to give great results within weeks.. Investors collecting them.. Be the first to collect there shares.. Not the last.. Good luck guys..
Reply
1 0
Report
Raul AlKhuwaitem
Raul AlKhuwaitem Feb 05, 2021 9:51AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Target price for some analysts above 15$.. Buy and hold guys..
Reply
4 0
Report
Gregor Samsa
Gregor Samsa Feb 05, 2021 9:51AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Which analysts?
Reply
0 0
Report
Roy mu
Roy mu Feb 05, 2021 9:51AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Gregor Samsa  You can check the street target almost from all finance websites, yahoo finance, or marketwatch. The target is at 4 to 5. 15 sounds like a fraud
Reply
0 0
Report
Konstantinos Theodorides
Konstantinos Theodorides Feb 05, 2021 5:25AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
its takeoff season🚀 specifically for a company that is Cancer research based with a strong volume.
Reply
1 0
Report
Raul AlKhuwaitem
Raul AlKhuwaitem Feb 05, 2021 1:49AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Baiden said we need too invest more in Medicine and Drogs to avoid any thing like Covid.. Be ready guys for wave of increase for Medicine and research Stocks like this stock.. Good luck guys..
Reply
2 0
Report
Apollofintrader xx
Apollofintrader xx Feb 04, 2021 3:04PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The volume is decente, just keep it for a natural grow.
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email